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Abstract 
 
Objective(s) 
This study aimed to investigate and to compare the effects of nifedipine and amlodipine, dihydropyridine 
(DHP) calcium channel blockers (CCBs) on perfusion pressure of isolated perfused rat kidney. 
Materials and Methods 
Following the establishment of renal perfusion with a constant baseline pressure of 85-95 mmHg, the renal 
vasculature was constricted by phenylephrine (PE) injection. Changes in the baseline perfusion pressure 
were recorded. Then nifedipine and amlodipine prepared in perfusion medium was fed to the kidney for 30 
min. Finally alterations in the baseline pressure arising from PE administrations in the presence of CCBs 
were recorded and data analyses were done. 
Results 
PE-induced increases in perfusion pressure attenuated significantly in the presence of 5 and 10 µM of 
nifedipine and 1, 5, and 10 µM of amlodipine. Increases in perfusion pressure arising from PE (100 and  200 
µM) in the presence of amlodipine (1, 5, and 10 µM) was significantly less than that in the presence of 
nifedipine (1, 5, and 10 µM). Calculated EC50 value of amlodipine for inhibition was significantly lower than 
that of nifedipine. Based on the EC50 values, the potency of amlodipine in inhibiting PE-induced responses is 
significantly higher compared to nifedipine. 
Conclusion 
The potency of amlodipine in inhibiting PE-induced increments in renal perfusion pressure is significantly 
higher compared to nifedipine. 
 
Keywords: Amlodipine, Isolated rat kidney, Nifedipine  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1- Department of Biology, Kazeroon Branch, Islamic Azad University, Kazeroon, Iran 
2- Razi Institute for Drug Research, Iran University of Medical Sciences, Tehran, Iran 
* Corresponding author: Tel: 88058696; Fax: 88052978; email: masmah99@iums.ac.ir 
3- Department of Physiology, Faculty of Veterinary Medicine, Tehran University, Tehran, Iran  
Lili Sepehr-Ara et al 
  Iran J Basic Med Sci, Vol. 13, No.1, Winter 2010    224 
Introduction          
Calcium-channel blockers (CCBs) have a 
significant role in the treatment of several 
cardiovascular and non-cardiovascular 
disorders (1, 2). These compounds are of 
special significant in the therapy of 
hypertension, angina pectoris and other 
cardiovascular disorders (1). These drugs also 
preserve or improve renal function in patients 
with essential hypertensive renal disease or 
diabetic renal disease. Studies in animal 
models of hypertension and in hypertensive 
humans have demonstrated reduction in renal 
vascular resistance, and preservation or 
enhancement of renal plasma flow (RPF), 
suggesting a relative renal selective action of 
these agents (3, 4).  
Among the classes of CCBs, 
dihydropyridine derivatives are widely used 
because of their potent vasodilating activity 
and weak cardiodepressant action (5). 
Dihydropyridines (DHPs) reduced Ca
2+ entry 
via L-type voltage gated Ca
2+  channels 
(LVGCs) in vascular smooth muscle cells. 
LVGCs mediate the depolarization-induced 
Ca
2+  entry and consequent vasoconstriction. 
Therefore DHPs markedly reduce myogenic 
tone which plays an important role in 
regulating blood flow and blood pressure (6). 
The prototype of DHPs, nifedipine, is 
clinically effective but has a number of 
undesirable pharmacokinetic and 
pharmacodynamic properties, which include a 
rapid onset of vasodilating action, a short half 
life and side effects such as reflex tachycardia, 
flushing, headache and dizziness (7, 8). 
Several  newer  1,4-DHP  analogues,              
which provide a reduction in adverse effects 
and exhibit more stable pharmacokinetics,              
have been developed and include amlodipine, 
lacidipine, nicardipine, nitrendipine (9).  
Amlodipine  (2-[(2-aminoethoxy)  methy]-            
4-(2-chlorophenyl)-3-ethixycarbonyl-5-2-
methoxycarbonyl-6-methyl-1,4 dihydropyridine) 
is a dihydropyridine derivative which is 
structurally related to other DHPs such as 
nifedipine but its chemical properties differ 
from typical DHPs (10). 
In vivo, the cardiovascular effects of 
amlodipine are largely due to vasodilation. 
This action of amlodipine is relatively slow in 
onset and of long duration (11). Similar 
vasorelaxant properties have been observed in 
vitro (10). Amlodipine has been shown to 
block L-type Ca
2+ channels selectively (12).  
Previous researches have shown that under 
angiotensin II  or norepinephrine-induced 
vasoconstrictor tone, both DHP classes               
(eg, nifedipine, nisoldipine, and amlodipine) and 
benzodiazepine class (eg, diltiazem) CCBs 
caused greater increases in glomerular filtration 
rate (GFR) than those in RPF. These 
observations indicated that these CCBs act 
predominantly on renal pre-glomerular vessels 
(13-16).  
In this study, effects of nifedipine and 
amlodipine on renal perfusion pressure in the 
isolated perfused rat kidney were investigated 
and compared with each other. Using this model 
it is possible to evaluate accurately the renal 
vasoconstriction modulation by CCBs elicited 
by different types of vasoconstrictor agents.  
 
Materials and Methods                 
Male wistar rats (300±10 g) having free access 
to food and tap water were anaesthetized with 
intraperitoneal injection of urethane               
(1.5 g/kg). After opening of the abdominal 
cavity by a ventricular incision, heparin was 
injected into the vena cava (500 U/kg) and 
renal artery was cannulated using a 20 G 
hypodermic needle with a polished tip via the 
superior mesenteric artery without disruption 
of flow. The ligatures around the cannula were 
tied and the kidney was removed and placed in 
a thermostated glass chamber contained 
perfusion medium at 37 ˚C. The perfusion 
medium consisted of Krebs solution with the 
following composition: NaCl (118 mM), KCl 
(4.8 mM), MgSO4, 7H2O (1.2 mM), CaCl2 
(2.5 mM), KH2PO4 (1.2 mM), NaHCO3 (25 
mM) and Glucose (10 mM) and equilibrated 
with 95٪ O2 and 5٪ CO2 (5).  
Perfusion was started in situ with a constant 
flow at 85-95 mmHg. Perfusion medium was 
fed to the kidney by means of a peristaltic 
pump (LKB, Varioperpex II) through PTFE 
tubings (Pharmacia Biotech, 18-8207-01).  
The  renal artery pressure was monitored 
through a pressure transducer (Beckman, 4-327)  
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situated parallel to perfusion cannula and was 
recorded on a Beckman polygraph (R-612).  
The drugs were injected by using a load-inject 
valve placed in the perfusion circuit, just before 
the kidney. The valve provides two flow paths. 
In the load position, the valve connects the pump 
directly to the kidney. Using a syringe, the 
sample drug is injected into a loop with a small 
defined volume. In the inject position, the 
sample in the loop is directly inserted into the 
flow path of the perfusate and does not alter the 
baseline pressure (17). 
In the method we used, following the 
establishment of isolated kidney perfusion and 
30 min equilibration, first the renal vasculature 
was constricted by injection of 0.5, 2, 5, 10, 
50,  100,  and  200  µM  phenylephrine                  
(α-agonist) to the perfusion line via load- 
inject pump. Changes in baseline pressure due 
to phenylephrine (PE) injection were recorded 
on a physiograph trace. Then DHPs calcium 
channel blockers nifedipine, and amlodipine 
(1, 5, and 10 µM) prepared in perfusion 
medium was fed to the kidney by a peristaltic 
pump for 30 min. Finally alterations in 
perfusion pressure from baseline due to PE 
administration via load-inject pump in the 
presence of CCBs were recorded. Of note, PE 
concentrations have been selected based on 
concentration response-curve and in higher 
concentrations of PE (>200 µM) the curve 
took a plateu shape. 
The DHPs were dissolved in 
dimethylsulfoxide (DMSO). Subsequent 
dilutions were made in krebs solution. 
Maximum increase in baseline perfusion 
pressure  arising from  PE injection in the 
absence of CCBs was considered as 100% of 
response.  PE-evoked increments in renal 
perfusion pressure in the absence or presence 
of CCBs were expressed as percent increase in 
perfusion pressure. Data (percent increments 
in perfusion pressure) were analysed by 
ANOVA using Nested design in MINITAB 
software.  
EC50 was used to measure the potency of 
these compounds by quantifying the inhibition 
of perfusion pressure arising from PE as the 
primary response as done by other authors 
(18). The observed increases in the perfusion 
pressure in the presence of increasing 
concentrations of DHPs were transformed into 
percent inhibition of perfusion pressure 
responses. These data also were analyzed as 
mentioned before. The EC50 values of CCBs 
were calculated by fitting the data points into 
logistic model curve with r values of not less 
than 0.94 using the Curve Expert 1.3 software 
and were analysed using Student’s t-test. All 
data were expressed as means±SEM. A 
P-value< 0.05 was considered to be 
significant.   
The animal experiments were in accordance 
with international guidelines and approved by 
the ethical committee of the Iranian University 
of Medical Sciences, Teheran, Iran.  
 
Results           
Our results indicated that the increases in 
perfusion pressure arising from PE administration 
attenuated significantly in the presence of 5, and 
10 µM of nifedipine (Figure 1). 
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Figure 1. The inhibitory effect of nifedipine on PE-
induced increases in perfusion pressure. Values are 
means±SEM from 5 kidneys.  Percent increases in 
perfusion pressure arising from PE decreased 
significantly in the presence of increasing 
concentrations of nifedipine (5 µM +P<0.001; 10 µM 
¼P<0.0001, vs. control group). Nifedipine at 5 µM 
shows significant difference with nifedipine at 1 µM 
(+P<0.001, error bars). PE-evoked increments in renal 
perfusion pressure in the presence or absence of CCBs 
were expressed as percent increase in perfusion 
pressure. 
 The signs across the curves show significant 
differences vs. control groups. 
 
 
PE-induced increases in perfusion pressure 
attenuated significantly in the presence of 1, 5, 
and 10 µM amlodipine (Figure 2). Amlodipine 
at 1 µM and 5 µM showed significant 
differences with each other (P<0.001).   
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Figure 2. The inhibitory effect of amlodipine on PE-
induced increases in perfusion pressure. Values are 
means±SEM from 5 kidneys. PE-induced increments in 
perfusion pressure attenuated significantly in the 
presence of increasing concentrations of amlodipine         
(+  P<0.001,  ¼P<0.0001, vs. control group). 
Amlodipine concentrations of 1 µM, and 5 µM differ 
significantly from each other (+P<0.001, *P<0.0001, 
error bars). The signs across the curves show significant 
differences vs. control groups. 
 
A sample trace representing the inhibitory 
effect of amlodipine on perfusion pressure rise 
induced by PE injection was shown in Figure 3.  
 
 
 
 
 
Figure 3.  A sample trace representing the inhibitory 
effect of amlodipine (10 µM) on increases in perfusion 
pressure  induced  by  increasing  concentration  of  PE        
[2 µM (A), 5 µM (B), 10 µM (C), 50 µM (D), 100 µM 
(E), 200 µM (F)]. PE-induced peak pressure rise in the 
absence of amlp (), PE-induced peak pressure rise in 
the presence of 10 µM amlp ( ). 
 
 
 
Our findings showed that PE-induced 
increments in perfusion pressure in the 
presence of amlodipine at all three 
administered doses, was significantly lower 
than that of nifedipine (1, 5 µM P<0.001;        
10 µM P<0.0001; Figures 4- 6).  
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Figure 4. The inhibitory effects of amlodipine and 
nifedipine (1 µM) on PE-induced increases in perfusion 
pressure. Values are means±SEM from 5 kidneys. 
Amlodipine (1 µM) significantly decreased PE-induced 
increments in perfusion pressure (P<0.05). The 
difference between amlodipine (1 µM) and nifedipine  
(1 µM) was significant in this respect (+P<0.001). 
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Figure. 5. The inhibitory effects of amlodipine and 
nifedipine (5 µM) on PE-induced increases in perfusion 
pressure. Values are means±SEM from 5 kidneys. 
nifedipine and amlodipine (5 µM) significantly 
decreased  PE-evoked responses (Nif. P<0.001; amlp. 
P<0.0001). The difference between amlodipine (5 µM) 
and nifedipine (5 µM) was significant in this respect 
(+P<0.001, *P<0.0001), reflecting that inhibitory effect 
of amlodipine (5 µM) on responses induced by PE               
(50, 100, 200 µM) was greater than that of nifedipine. 
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Figure 6. The inhibitory effects of amlodipine and 
nfedipine (10 µM) on PE-induced increases in perfusion 
pressure. Values are means±SEM from 5 kidneys. 
Nifedipine and amlodipine (10 µM) significantly inhibited 
PE-induced responses (P<0.0001). The data analysis 
indicated that nifidipine (10 µM) and amlodipine (10 µM) 
were significantly different from each other (*P<0.0001). 
Consequently inhibitory effect of amlodipine (10 µM) on 
responses induced by PE was greater than that of 
nifedipine (10 µM).  
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EC50  was used to measure the potency of 
these compounds by quantifying the inhibition 
of perfusion pressure arising from PE as the 
primary response as done by other authors 
(18). The concentration-response curve for 
DHP-induced inhibition (1-10 µM) exhibited a 
half maximal response (EC50) of 2.17±0.73, 
and 4.4±0.32 for amlodipine and nifedipine, 
respectively (Figure 7).  EC50 value of 
amlodipine for inhibition was significantly 
lower than that of nifedipine, indicating that 
amlodipine has more potency in inhibiting PE-
induced responses as compared to nifedipine 
(P<0.001).  
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Figure 7. The concentration-response curve for DHP-
induced inhibition. Values are means±SEM from 5 
kidneys. Data analysis showed that inhibitory effects of 
increasing concentrations of amlodipine on PE-induced 
pressure responses (Emax  of PE) were significantly 
greater than that of nifedipine (×P<0.01, *P<0.0001). 
Calculated EC50 of amlodipine for inhibition was 
significantly lower than that of nifedipine (P<0.001).  
 
 
Discussion  
Calcium channel blockers (CCB) are clinically 
useful vasodilators, used widely in the 
treatment of hypertension. These agents are 
reported to preserve or even increase renal 
blood flow in the face of reduction in systemic 
blood pressure (4). Previous studies have 
shown that amlodipine a CCB of DHP 
chemical class, inhibited calcium currents in 
single vascular smooth muscle cells isolated 
from rabbit ear artery (10). It was found that 
amlodipine selectively blocks L-type Ca
2+ 
channels (12, 19).  
Present study indicated that amlodipine,           
a  dihydropiridine  derivative  inhibited                  
PE-induced increments in perfusion pressure 
in isolated perfused rat kidney. Nifedipine also 
reduced responses to PE. DHPs reduced Ca
2+ 
entry via L-type voltage gated Ca
2+ channels 
(6). Amlodipine is shown to selectively block 
L-type Ca
2+ channels (12).  
A recent study implies that Ca
2+ entry via 
Cav1.2 LVGCs
 is obligatory for myogenic tone 
and nifedipine inhibits myogenic tone 
exclusively
 by blocking LVGCs and not other 
Ca
2+ entry channels. It also implies that the 
DHP receptors
  on Cav1.2 channels are 
necessary and sufficient for nifedipine
 block of 
VGCs in mesenteric small arteries (6).  
Our findings showed that the inhibitory effect 
of amlodipine on PE-induced increases in 
perfusion pressure was greater than that of 
nifedipine. Based on the EC50 values, 
amlodipine is more potent in inhibiting response 
to PE compared to nifedipine. Amlodipine has 
more vasoselectivity property compared to 
nifedipine (20). Tissue selectivity improves 
pharmacokinetic parameters and gives some 
additional properties to the molecule (21). 
It has been reported that dihydropirydine-
class (nifedipine and amlodipine) caused 
predominant vasodilation of the afferent 
arteriole in isolated perfused hydronephrotic 
kidney (22). Since the traditional calcium 
antagonists (e.g. nifedipine) act on L-type 
voltage dependent calcium channel and these 
channels prevail predominantly at the afferent 
arteriole (23, 24). The effects on the efferent 
arteriole by these calcium antagonists are most 
likely attributed to additional actions of these 
antagonists, but not due to the class affects of 
these agents (4). 
Amlodipine  is  a  longer-acting  CCB,  with          
a longer in vivo elimination half-life, than 
nifedipine (25). Although it is a 
dihydropyridine, the action of amlodipine may 
also involve binding to non- dihydropyridine 
sites on the voltage-operated calcium channel. 
Ligand binding studies indicate that 
amlodipine interacts not only with a 
dihydropyridine binding site but also with a 
site which binds to diltiazem (26) and another 
that binds to phenylalkylamines such as (-)-
D888 (27). 
Amlodipine is demonstrated to posses an 
inhibitory action on both L-type and N-type  
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Ca channels (28). It is also reported to cause a 
substantial dilation of efferent as well as 
afferent arterioles in the in vivo hydronephrotic 
kidney (29). 
However amlodipine vasodilatory properties 
have been ascribed to it’s inhibitory action on 
voltage-gated calcium channels in vascular 
smooth muscle. Some studies have suggested 
that amlodipine has an additional vasodilatory 
effect through stimulation of nitric oxide (NO) 
release from vascular endothelium. It was found 
that amlodipine unlike nifedipine increases 
nitrite production from healthy canine coronary 
microvesseles in vitro, expressing an increase in 
NO biosynthesis (30). A recent study has 
demonstrated that the vasorelaxant effects of 
amlodipine unlike nifedipine are partly 
dependent on NO generation in rabbit femora 
artery in vivo. This effect of amlodipine occurs 
through  β2 receptor activation and may be 
related to an increase in local bradykinin (25). 
These findings indicate that this compound acts 
as two enantiomers, one with the ability to block 
L-type Ca channels whilst the other has NO 
releasing property (31). 
 
Conclusion 
The present study demonstrates that 
amlodipine  is  more  potent  in  inhibiting        
PE-induced increments in renal perfusion 
pressure compared to nifedipine. In other 
words, amlodipine has more ability to decrease 
renal microvascular resistance compared to 
nifedipine.  
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